Tisdale J.E., Miller D.A. (eds.) Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda: ASHP; 2018. 1399 р. Available at: https://tetondata.com/TitleInfo.cshtml?id=285.https://tetondata.com/TitleInfo.cshtml?id=285
Tisdale J.E., Miller D.A. (eds.) Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda: ASHP; 2018. 1399 р. Available at: https://tetondata.com/TitleInfo.cshtml?id=285.https://tetondata.com/TitleInfo.cshtml?id=285
Shin H.W., Chung S.J. Drug-induced parkinsonism. J Clin Neurol. 2015;36(2):269–274. https://doi.org/10.1007/s10072-014-1945-8..
DOI: 10.1007/s10072-014-1945-8
de Germay S., Montastruc F., Carvajal A., Lapeyre-Mestre M., Montastruc J.L. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020;70:55–59. https://doi.org/10.1016/j.parkreldis.2019.12.011..
DOI: 10.1016/j.parkreldis.2019.12.011
Левин О.С., Шиндряева Н.Н., Аникина М.А. Лекарственный паркинсонизм. Журнал неврологии и психиатрии имени С.С. Корсакова. 2012;112(8):76–81. Режим доступа: https://elibrary.ru/item.asp?id=18000440.https://elibrary.ru/item.asp?id=18000440
Левин О.С., Шиндряева Н.Н., Аникина М.А. Лекарственный паркинсонизм. Журнал неврологии и психиатрии имени С.С. Корсакова. 2012;112(8):76–81. Режим доступа: https://elibrary.ru/item.asp?id=18000440.https://elibrary.ru/item.asp?id=18000440
Нодель М.Р. Лекарственный паркинсонизм: возможности минимизации риска. Нервные болезни. 2015;(3):18–23. Режим доступа: https://elibrary.ru/item.asp?id=25088710.https://elibrary.ru/item.asp?id=25088710
Нодель М.Р. Лекарственный паркинсонизм: возможности минимизации риска. Нервные болезни. 2015;(3):18–23. Режим доступа: https://elibrary.ru/item.asp?id=25088710.https://elibrary.ru/item.asp?id=25088710
Kumsa A., Girma S., Alemu B., Agenagnew L. Psychotropic medicationsinduced tardive dyskinesia and associated factors among patients with mental illness in Ethiopia. Clin Pharmacol. 2020;12:179–187. https://doi.org/10.2147/CPAA.S285585..
DOI: 10.2147/CPAA.S285585
Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. https://doi.org/10.1016/S0140-6736(13)60733-3..
DOI: 10.1016/S0140-6736(13)60733-3
Chyou T.Y., Nishtala R., Nishtala P.S. Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study. Pharmacoepidemiol Drug Saf. 2020;29(6):692–700. https://doi.org/10.1002/pds.5007..
DOI: 10.1002/pds.5007
Bondon-Guitton E., Perez-Lloret S., Bagheri H., Brefel C., Rascol O., Montastruc J.L. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226–2231. https://doi.org/10.1002/mds.23828..
DOI: 10.1002/mds.23828
Leung J.G., Breden E.L. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011;45(4):525–531. https://doi.org/10.1345/aph.1P312..
DOI: 10.1345/aph.1P312
Sahin T., Yilmaz R., Akbostanci M.C. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders. Parkinsonism Relat Disord. 2020;74:36–37. https://doi.org/10.1016/j.parkreldis.2020.04.007..
DOI: 10.1016/j.parkreldis.2020.04.007
Guay D.R. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8(4):331–373. https://doi.org/10.1016/j.amjopharm.2010.08.006..
DOI: 10.1016/j.amjopharm.2010.08.006
Kenney C., Hunter C., Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193–197. https://doi.org/10.1002/mds.21222..
DOI: 10.1002/mds.21222
Teive H.A., Troiano A.R., Germiniani F.M., Werneck L.C. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord. 2004;10(4):243–245. https://doi.org/10.1016/j.parkreldis.2003.12.004..
DOI: 10.1016/j.parkreldis.2003.12.004
Lin H.L., Lin H.C., Tseng Y.F., Chen S.C., Hsu C.Y. Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study. Eur J Clin Pharmacol. 2017;73(3):365–371. https://doi.org/10.1007/s00228-016-2181-3..
DOI: 10.1007/s00228-016-2181-3
Jhang K.M., Huang J.Y., Nfor O.N., Tung Y.C., Ku W.Y., Lee C.T., Liaw Y.P. Extrapyramidal symptoms after exposure to calcium channel blockerflunarizine or cinnarizine. Eur J Clin Pharmacol. 2017;73(7):911–916. https://doi.org/10.1007/s00228-017-2247-x..
DOI: 10.1007/s00228-017-2247-x
Miguel R., Correia A.S., Bugalho P. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine. J Parkinsons Dis. 2014;4(4):645–649. https://doi.org/10.3233/JPD-140414..
DOI: 10.3233/JPD-140414
Cardoso F., Camargos S.T., Silva Júnior G.A. Etiology of parkinsonism in a Brazilian movement disorders clinic. Arq Neuropsiquiatr. 1998;56(2):171–175. https://doi.org/10.1590/s0004-282x1998000200001..
DOI: 10.1590/s0004-282x1998000200001
Negrotti A., Calzetti S. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord. 1997;12(1):107–110. https://doi.org/10.1002/mds.870120119..
DOI: 10.1002/mds.870120119
Kim S., Cheon S.M., Suh H.S. Association between drug exposure and occurrence of parkinsonism in Korea: a population-based case-control study. Ann Pharmacother. 2019;53(11):1102–1110. https://doi.org/10.1177/1060028019859543..
DOI: 10.1177/1060028019859543
Jhang K.M., Huang J.Y., Nfor O.N., Tung Y.C., Ku W.Y., Jan C.F., Liaw Y.P. Flunarizine related movement disorders: a nationwide population-based study. Sci Rep. 2019;9(1):1705. https://doi.org/10.1038/s41598-018-37901-z..
DOI: 10.1038/s41598-018-37901-z
Lin W., Lin C.L., Hsu C.Y., Wei C.Y. Flunarizine Induced Parkinsonism in Migraine Group: A Nationwide Population-Based Study. Front Pharmacol. 2019;10:1495. https://doi.org/10.3389/fphar.2019.01495..
DOI: 10.3389/fphar.2019.01495
Liang C.Y., Yeh Y.C., Lee C.J., Chen Y.Y. Flunarizine and the risk of parkinsonism in a newly diagnosed type 2 diabetic population in Taiwan: A nested case-control study. J Clin Neurosci. 2018;50:281–286. https://doi.org/10.1016/j.jocn.2018.01.017..
DOI: 10.1016/j.jocn.2018.01.017
Giménez-Roldán S., Mateo D. Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor. Clin Neuropharmacol. 1991;14(2):156–164. https://doi.org/10.1097/00002826-199104000-00005..
DOI: 10.1097/00002826-199104000-00005
Martí-Massó J.F., Poza J.J. Cinnarizine-induced parkinsonism: ten years later. Mov Disord. 1998;13(3):453–456. https://doi.org/10.1002/mds.870130313..
DOI: 10.1002/mds.870130313
Padrell M.D., Navarro M., Faura C.C., Horga J.F. Verapamil-induced parkinsonism. Am J Med. 1995;99(4):436. https://doi.org/10.1016/s0002-9343(99)80195-8..
DOI: 10.1016/s0002-9343(99)80195-8
Revet A., Montastruc F., Roussin A., Raynaud J.P., Lapeyre-Mestre M., Nguyen T.T. H. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020;20(1):308. https://doi.org/10.1186/s12888-020-02711-z..
DOI: 10.1186/s12888-020-02711-z
Miletić V., Relja M. Citalopram-induced parkinsonian syndrome: case report. Clin Neuropharmacol. 2011;34(2):92–93. https://doi.org/10.1097/WNF.0b013e318210ea3e..
DOI: 10.1097/WNF.0b013e318210ea3e
Damali Amiri N., Wijenaike N. Citalopram-induced hyponatraemia and parkinsonism: potentially fatal side-effects not to be missed. BMJ Case Rep. 2014;2014:bcr2014206575. https://doi.org/10.1136/bcr-2014-206575..
DOI: 10.1136/bcr-2014-206575
Ak S., Anıl Yağcıoğlu A.E. Escitalopram-induced Parkinsonism. Gen Hosp Psychiatry. 2014;36(1):126.e1-2. https://doi.org/10.1016/j.genhosppsych.2013.09.010..
DOI: 10.1016/j.genhosppsych.2013.09.010
Kuloglu M., Caykoylu A., Ekinci O., Bayindirli D., Vural G., Deniz O. Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use. J Psychopharmacol. 2010;24(4):623–624. https://doi.org/10.1177/0269881108099962..
DOI: 10.1177/0269881108099962
Gernaat H.B., Van de Woude J., Touw D.J. Fluoxetine and parkinsonism in patients taking carbamazepine. Am J Psychiatry. 1991;148(11):1604–1605. https://doi.org/10.1176/ajp.148.11.1604b..
DOI: 10.1176/ajp.148.11.1604b
Christodoulou C., Papadopoulou A., Rizos E., Tournikioti K., Gonda X., Douzenis A., Lykouras L. Extrapyramidal side effects and suicidal ideation under fluoxetine treatment: a case report. Ann Gen Psychiatry. 2010;9:5. https://doi.org/10.1186/1744-859X-9-5..
DOI: 10.1186/1744-859X-9-5
Gray J.A. Parkinsonism and rabbit syndrome after discontinuation of lowdose ziprasidone and concomitant initiation of sertraline. J Clin Psychopharmacol. 2012;32(1):142–143. https://doi.org/10.1097/JCP.0b013e31823f912a..
DOI: 10.1097/JCP.0b013e31823f912a
Di Rocco A., Brannan T., Prikhojan A., Yahr M.D. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm (Vienna). 1998;105(2-3):247–251. https://doi.org/10.1007/s007020050053..
DOI: 10.1007/s007020050053
Pina Latorre M.A., Modrego P.J., Rodilla F., Catalán C., Calvo M. Parkinsonism and Parkinson’s disease associated with long-term administration of sertraline. J Clin Pharm Ther. 2001;26(2):111–112. https://doi.org/10.1046/j.1365-2710.2001.00307.x..
DOI: 10.1046/j.1365-2710.2001.00307.x
Mendhekar D.N., Benuiwal R.P., Puri V. Parkinsonism and elevated lactic acid with sertraline. Can J Psychiatry. 2005;50(5):301. https://doi.org/10.1177/070674370505000516..
DOI: 10.1177/070674370505000516
Schechter D.S., Nunes E.V. Reversible parkinsonism in a 90-year-old man taking sertraline. J Clin Psychiatry. 1997;58(6):275. https://doi.org/10.4088/jcp.v58n0607f..
DOI: 10.4088/jcp.v58n0607f
Bayrak A., Cetin B., Meteris H., Kesebir S. Parkinsonism secondary to duloxetine use: a case report. North Clin Istanb. 2015;2(3):243–246. https://doi.org/10.14744/nci.2015.63634..
DOI: 10.14744/nci.2015.63634
Hong J.Y., Sunwoo M.K., Oh J.S., Kim J.S., Sohn Y.H., Lee P.H. Persistent druginduced parkinsonism in patients with normal dopamine transporter imaging. PLoS ONE. 2016;11(6):e0157410. https://doi.org/10.1371/journal.pone.0157410..
DOI: 10.1371/journal.pone.0157410
Sarwar A.I. Trazodone and parkinsonism: the link strengthens. Clin Neuropharmacol. 2018;41(3):106–108. https://doi.org/10.1097/WNF.0000000000000278..
DOI: 10.1097/WNF.0000000000000278
Albanese A., Rossi P., Altavista M.C. Can trazodone induce parkinsonism? Clin Neuropharmacol. 1988;11(2):180–182. https://doi.org/10.1097/00002826-198804000-00010..
DOI: 10.1097/00002826-198804000-00010
Sotto Mayor J., Pacheco A.P., Esperança S., Oliveira e Silva A. Trazodone in the elderly: risk of extrapyramidal acute events. BMJ Case Rep. 2015;2015:bcr2015210726. https://doi.org/10.1136/bcr-2015-210726..
DOI: 10.1136/bcr-2015-210726
Brugger F., Bhatia K.P., Besag F.M. Valproate-associated parkinsonism: a critical review of the literature. CNS Drugs. 2016;30(6):527–540. https://doi.org/10.1007/s40263-016-0341-8..
DOI: 10.1007/s40263-016-0341-8
Yomtoob J., Koloms K., Bega D. DAT-SPECT imaging in cases of druginduced parkinsonism in a specialty movement disorders practice. Parkinsonism Relat Disord. 2018;53:37–41. https://doi.org/10.1016/j.parkreldis.2018.04.037..
DOI: 10.1016/j.parkreldis.2018.04.037
Ristić A.J., Vojvodić N., Janković S., Sindelić A., Sokić D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia. 2006;47(12):2183–2185. https://doi.org/10.1111/j.1528-1167.2006.00711.x..
DOI: 10.1111/j.1528-1167.2006.00711.x
Muralidharan A., Rahman J., Banerjee D., Hakim Mohammed A.R., Malik B.H. Parkinsonism: a rare adverse effect of valproic acid. Cureus. 2020;12(6):e8782. Available at: https://pubmed.ncbi.nlm.nih.gov/32724733.https://pubmed.ncbi.nlm.nih.gov/32724733
Muralidharan A., Rahman J., Banerjee D., Hakim Mohammed A.R., Malik B.H. Parkinsonism: a rare adverse effect of valproic acid. Cureus. 2020;12(6):e8782. Available at: https://pubmed.ncbi.nlm.nih.gov/32724733.https://pubmed.ncbi.nlm.nih.gov/32724733
Pacheco-Paez T., Montastruc F., Rousseau V., Chebane L., LapeyreMestre M., Renoux C., Montastruc J.L. Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study. Mov Disord. 2020;35(1):176–180. https://doi.org/10.1002/mds.27876..
DOI: 10.1002/mds.27876
Rissardo J.P., Caprara A.L. F. Carbamazepine-, oxcarbazepine-, eslicarbazepine-associated movement disorder: a literature review. Clin Neuropharmacol. 2020;43(3):66–80. https://doi.org/10.1097/WNF.0000000000000387..
DOI: 10.1097/WNF.0000000000000387
Tsai S.C., Sheu S.Y., Chien L.N., Lee H.C., Yuan E.J., Yuan R.Y. High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study. Br J Clin Pharmacol. 2018;84(9):2000–2009. https://doi.org/10.1111/bcp.13630..
DOI: 10.1111/bcp.13630
Lai C.H., Yeh Y.C., Chen Y.Y. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019;10:2042098619854007. https://doi.org/10.1177/2042098619854007..
DOI: 10.1177/2042098619854007
Kane J., Rifkin A., Quitkin F., Klein D.F. Extrapyramidal side effects with lithium treatment. Am J Psychiatry. 1978;135(7):851–853. https://doi.org/10.1176/ajp.135.7.851..
DOI: 10.1176/ajp.135.7.851
Reches A., Tietler J., Lavy S. Parkinsonism due to lithium carbonate poisoning. Arch Neurol. 1981;38(7):471. https://doi.org/10.1001/archneur.1981.00510070105031..
DOI: 10.1001/archneur.1981.00510070105031
Gmitterová K., Minár M., Žigrai M., Košutzká Z., Kušnírová A., Valkovič P. Tacrolimus-induced parkinsonism in a patient after liver transplantation – case report. BMC Neurol. 2018;18(1):44. https://doi.org/10.1186/s12883-018-1052-1..
DOI: 10.1186/s12883-018-1052-1
Diaz-Segarra N., Edmond A., Yonclas P. Functional improvement of tacrolimus-induced parkinsonism with amantadine after liver transplantation: a case report. Clin Neuropharmacol. 2021;44(4):141–144. https://doi.org/10.1097/WNF.0000000000000444..
DOI: 10.1097/WNF.0000000000000444
Marras C., Herrmann N., Fischer H.D., Fung K., Gruneir A., Rochon P.A. et al. Lithium use in older adults is associated with increased prescribing of parkinson medications. Am J Geriatr Psychiatry. 2016;24(4):301–309. https://doi.org/10.1016/j.jagp.2015.11.004..
DOI: 10.1016/j.jagp.2015.11.004
Miyagi S., Sekiguchi S., Kawagishi N., Akamatsu Y., Sato A., Fujimori K., Satomi S. Parkinsonism during cyclosporine treatment in liver transplantation: an unusual case report. Transplant Proc. 2008;40(8):2823–2824. https://doi.org/10.1016/j.transproceed.2008.07.053..
DOI: 10.1016/j.transproceed.2008.07.053
Kim H.C., Han S.Y., Park S.B., Suh S.J. Parkinsonism during cyclosporine treatment in renal transplantation. Nephrol Dial Transplant. 2002;17(2):319–321. https://doi.org/10.1093/ndt/17.2.319..
DOI: 10.1093/ndt/17.2.319
Ling H., Bhidayasiri R. Reversible Parkinsonism after chronic cyclosporin treatment in renal transplantation. Mov Disord. 2009;24(12):1848–1849. https://doi.org/10.1002/mds.22530..
DOI: 10.1002/mds.22530
Montastruc J.L., Durrieu G. Amiodarone and Parkinsonism: a pharmacovigilance study. Fundam Clin Pharmacol. 2021;35(4):781–784. https://doi.org/10.1111/fcp.12618..
DOI: 10.1111/fcp.12618
Werner E.G., Olanow C.W. Parkinsonism and Amiodarone Therapy. Ann Neurol. 1989;25(6):630–632. https://doi.org/10.1002/ana.410250618..
DOI: 10.1002/ana.410250618
Dotti M.T., Federico A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disorders. 1995;10(2):233–234. https://doi.org/10.1002/mds.870100223..
DOI: 10.1002/mds.870100223
Malaterre H.R., Renou C., Kallee K., Gauthier A. Akinesia and amiodarone therapy. Int J Cardiol. 1997;59(1):107–108. https://doi.org/10.1016/s0167-5273(96)02891-4..
DOI: 10.1016/s0167-5273(96)02891-4
Ishida S., Sugino M., Hosokawa T., Sato T., Furutama D., Fukuda A. et al. Amiodarone-induced liver cirrhosis and parkinsonism: a case report. Clin Neuropathol. 2010;29(2):84–88. https://doi.org/10.5414/npp29084..
DOI: 10.5414/npp29084
Sandyk R. Parkinsonism induced by captopril. Clin Neuropharmacol. 1985;8(2):197. https://doi.org/10.1097/00002826-198506000-00013..
DOI: 10.1097/00002826-198506000-00013
Fisher J.F., Dewald J. Parkinsonism associated with intraventricular amphotericin B. J Antimicrob Chemother. 1983;12(1):97–99. https://doi.org/10.1093/jac/12.1.97..
DOI: 10.1093/jac/12.1.97
Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. https://doi.org/10.1038/clpt.1981.154..
DOI: 10.1038/clpt.1981.154
Сычев Д.А., Остроумова О.Д., Переверзев А.П., Кочетков А.И., Остроумова Т.М., Клепикова М.В. и др. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фарматека. 2020;(6):113–126. https://doi.org/10.18565/pharmateca.2020.6.113-126..
DOI: 10.18565/pharmateca.2020.6.113-126
The American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 3d ed. Washington: American Psychiatric Association; 2021. 312 p. https://doi.org/appi.books.9780890424841..
DOI: appi.books.9780890424841